PH26517A - Methods and composition for the treatment of psoriasis - Google Patents
Methods and composition for the treatment of psoriasis Download PDFInfo
- Publication number
- PH26517A PH26517A PH37032A PH37032A PH26517A PH 26517 A PH26517 A PH 26517A PH 37032 A PH37032 A PH 37032A PH 37032 A PH37032 A PH 37032A PH 26517 A PH26517 A PH 26517A
- Authority
- PH
- Philippines
- Prior art keywords
- psoriasis
- azidothymidine
- treatment
- abated
- dosage form
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 52
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 57
- 229960002555 zidovudine Drugs 0.000 claims abstract description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 239000006208 topical dosage form Substances 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 239000002674 ointment Substances 0.000 claims abstract description 10
- 230000002682 anti-psoriatic effect Effects 0.000 claims abstract description 8
- 230000003902 lesion Effects 0.000 claims abstract description 7
- 239000003246 corticosteroid Substances 0.000 claims abstract description 6
- 239000006071 cream Substances 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 230000007794 irritation Effects 0.000 claims abstract description 5
- 239000006210 lotion Substances 0.000 claims abstract description 5
- 239000006072 paste Substances 0.000 claims description 4
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 3
- 229930003836 cresol Natural products 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 150000002989 phenols Chemical class 0.000 claims description 3
- 229960002311 dithranol Drugs 0.000 claims description 2
- 239000005864 Sulphur Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 9
- 239000003410 keratolytic agent Substances 0.000 abstract description 2
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000006201 parenteral dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 238000001990 intravenous administration Methods 0.000 description 16
- 208000030507 AIDS Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010001513 AIDS related complex Diseases 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 4
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 201000000317 pneumocystosis Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- NFXAJWJJNLWLOV-LHBOOPKSSA-N Zidovudine glucuronide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)[C@@H](N=[N+]=[N-])C1 NFXAJWJJNLWLOV-LHBOOPKSSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011269 tar Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010058667 Oral toxicity Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QQOBRRFOVWGIMD-OJAKKHQRSA-N azaribine Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=N1 QQOBRRFOVWGIMD-OJAKKHQRSA-N 0.000 description 2
- 229950010054 azaribine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 231100000418 oral toxicity Toxicity 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010037855 Rash erythematous Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- HWOLQKJPMRZMEX-PJKMHFRUSA-N diazonio-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]azanide Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(N=[N+]=[N-])O[C@H](CO)[C@@H](O)C1 HWOLQKJPMRZMEX-PJKMHFRUSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005655 esophageal candidiasis Diseases 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 231100000067 mild irritant Toxicity 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/059,907 US4804651A (en) | 1987-06-09 | 1987-06-09 | Methods and compositions for the treatment of psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26517A true PH26517A (en) | 1992-08-07 |
Family
ID=22026060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH37032A PH26517A (en) | 1987-06-09 | 1988-08-08 | Methods and composition for the treatment of psoriasis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4804651A (de) |
| EP (1) | EP0301206B1 (de) |
| JP (1) | JP2510675B2 (de) |
| KR (1) | KR950014447B1 (de) |
| AT (1) | ATE71301T1 (de) |
| AU (1) | AU606423B2 (de) |
| DE (1) | DE3867560D1 (de) |
| DK (1) | DK310188A (de) |
| ES (1) | ES2038716T3 (de) |
| GR (1) | GR3003785T3 (de) |
| HU (1) | HU200693B (de) |
| IE (1) | IE61091B1 (de) |
| MY (1) | MY103734A (de) |
| PH (1) | PH26517A (de) |
| ZA (1) | ZA884056B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527779A (en) * | 1988-03-23 | 1996-06-18 | Top Gold Pty Limited | Topically applied gold organic complex |
| ATE168698T1 (de) * | 1988-05-27 | 1998-08-15 | Us Health | Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten |
| US5098899A (en) * | 1989-03-06 | 1992-03-24 | Trustees Of Boston University | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites |
| JP2831030B2 (ja) * | 1989-05-12 | 1998-12-02 | 学校法人城西大学 | ３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物 |
| US5021422A (en) * | 1989-06-08 | 1991-06-04 | Senetek Plc | Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins |
| US5162361A (en) * | 1990-04-10 | 1992-11-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method of treating diseases associated with elevated levels of interleukin 1 |
| EP0663831A1 (de) * | 1991-12-13 | 1995-07-26 | G.D. Searle & Co. | Azidothymidin zur transdermalen Verabreichung |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| US5973010A (en) * | 1998-05-15 | 1999-10-26 | Crawford; Robert L. | Composition for healing skin wounds |
| GR1003491B (el) * | 1999-12-21 | 2000-11-30 | Μεθοδος παρασκευης φαρμακοτεχνικου σκευασματος, αλοιφης η κρεμασκαι χρηση του στην αντιμετωπιση και θεραπεια της ψωριασεως και του εκζεματος | |
| JP2009528382A (ja) * | 2006-03-01 | 2009-08-06 | トリストラータ・インコーポレイテッド | タール応答性皮膚疾患の局所治療のための組成物及び方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1285935C (en) * | 1985-03-16 | 1991-07-09 | Janet Lister Rideout | Therapeutic nucleosides |
| IL85738A0 (en) * | 1987-03-16 | 1988-08-31 | Wellcome Found | Nucleoside derivatives,their preparation and pharmaceutical compositions containing them |
-
1987
- 1987-06-09 US US07/059,907 patent/US4804651A/en not_active Expired - Lifetime
-
1988
- 1988-06-07 AT AT88109039T patent/ATE71301T1/de not_active IP Right Cessation
- 1988-06-07 EP EP88109039A patent/EP0301206B1/de not_active Expired - Lifetime
- 1988-06-07 ZA ZA884056A patent/ZA884056B/xx unknown
- 1988-06-07 DE DE8888109039T patent/DE3867560D1/de not_active Expired - Lifetime
- 1988-06-07 ES ES88109039T patent/ES2038716T3/es not_active Expired - Lifetime
- 1988-06-08 DK DK310188A patent/DK310188A/da not_active Application Discontinuation
- 1988-06-08 MY MYPI88000622A patent/MY103734A/en unknown
- 1988-06-08 IE IE170888A patent/IE61091B1/en not_active IP Right Cessation
- 1988-06-08 AU AU17510/88A patent/AU606423B2/en not_active Expired
- 1988-06-09 HU HU882990A patent/HU200693B/hu not_active IP Right Cessation
- 1988-06-09 JP JP63142729A patent/JP2510675B2/ja not_active Expired - Lifetime
- 1988-06-09 KR KR1019880006883A patent/KR950014447B1/ko active IP Right Grant
- 1988-08-08 PH PH37032A patent/PH26517A/en unknown
-
1992
- 1992-02-11 GR GR920400211T patent/GR3003785T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK310188D0 (da) | 1988-06-08 |
| KR890000093A (ko) | 1989-03-11 |
| MY103734A (en) | 1993-09-30 |
| ATE71301T1 (de) | 1992-01-15 |
| AU606423B2 (en) | 1991-02-07 |
| KR950014447B1 (ko) | 1995-11-28 |
| DE3867560D1 (de) | 1992-02-20 |
| EP0301206A2 (de) | 1989-02-01 |
| IE881708L (en) | 1988-12-09 |
| GR3003785T3 (de) | 1993-03-16 |
| JPS6470417A (en) | 1989-03-15 |
| JP2510675B2 (ja) | 1996-06-26 |
| US4804651A (en) | 1989-02-14 |
| HU200693B (en) | 1990-08-28 |
| EP0301206A3 (en) | 1989-09-06 |
| IE61091B1 (en) | 1994-09-21 |
| DK310188A (da) | 1988-12-12 |
| EP0301206B1 (de) | 1992-01-08 |
| HUT47853A (en) | 1989-04-28 |
| ZA884056B (en) | 1989-06-28 |
| ES2038716T3 (es) | 1995-04-01 |
| AU1751088A (en) | 1988-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6143738A (en) | Therapeutic uses for an aminosterol compound | |
| Hochster et al. | Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS clinical trials group study | |
| DE69010162T2 (de) | Zusammensetzung zur Behandlung von Entzündung. | |
| KR20020031331A (ko) | 미토콘드리아 관련 질환의 치료방법 | |
| GRUPE et al. | Cytotoxic drugs in steroid-resistant renal disease: alkylating and antimetabolic agents in the treatment of nephrotic syndrome, lupus nephritis, chronic glomerulonephritis, and purpura nephritis in children | |
| US20050220895A1 (en) | Use of gallium to treat inflammatory arthritis | |
| PH26517A (en) | Methods and composition for the treatment of psoriasis | |
| Jacobson et al. | Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease | |
| US3868454A (en) | Psoriasis treatment with mycophenolic acid derivatives | |
| EP0399051B1 (de) | Polyvalentes entzündungshemmendes mittel | |
| AU721841B2 (en) | A pharmaceutical composition for the treatment of autoimmune diseases | |
| EP0038567B1 (de) | Deazapurin-Nukleosid, es enthaltende Zusammensetzungen und seine therapeutische Verwendung | |
| US20030207819A1 (en) | Compositions and methods for treating inflammatory connective tissue diseases | |
| US20040014681A1 (en) | Method for treating dermatoses and tissue damage | |
| WO1997044044A1 (en) | Therapeutic uses for an aminosterol compound | |
| DE69316729T2 (de) | Zusammensetzungen und verfahren zur behandlung von autoimmunkrankheiten | |
| EP3479826B1 (de) | Verwendung von methyl-4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrat zur herstellung eines medikaments zur behandlung von psoriasis und vitiligo | |
| Epstein | Synthetic antimalarial drug therapy in lupus erythematosus and polymorphous light eruptions | |
| US5494936A (en) | Delivery formulation for probucol | |
| DE3736691A1 (de) | Oestradiolderivathaltiger immunregulator | |
| KR100245670B1 (ko) | 종양괴사인자 매개성 피부질환 치료제 조성물 | |
| CH669909A5 (de) | ||
| JP2816499B2 (ja) | 糖尿病治療剤 | |
| Lincoln Jr et al. | TREATMENT OF ITCHING—A Preliminary Report on Results with a New Oral Antipruritic | |
| EP1513539B1 (de) | Verwendung von amphiphilen nucleosid-phosphonoameisensäure-derivaten zur behandlung von viralen infektionskrankheiten |